Can ibrutinib be purchased in domestic hospitals?

Ibrutinib (Ibrutinib) is a targeted therapy drug that belongs to the BTK inhibitor class. It is widely used to treat certain types of leukemias and lymphomas, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), adjuvantCLL span>T cell lymphoma (MCL) and mucosa-associated lymphoid tissue lymphoma (MALTlymphoma), etc.

Ibrutinib can be purchased in domestic hospital pharmacies. Ibrutinib is a prescription drug that requires a prescription from a doctor, but the domestic price is relatively high. Ibrutinib is currently on the market in China and is included in medical insurance. The domestic price ranges from 10,000 to 20,000. Due to different medical insurance policies in different places, the price is also different. For specific reimbursement information, please consult the local hospital pharmacy or medical insurance bureau. The cheaper types of ibrutinib abroad are generic drugs, mainly Indian generic drugs, Bangladeshi generic drugs and Laos generic drugs, with prices ranging from a few hundred to several thousand yuan. And the ingredients of generic ibrutinib drugs are basically the same as those of domestic ibrutinib drugs.

Ibrutinib's main mechanism of action is to inhibit the activity ofBTKenzyme, a protein that plays a key role in leukemia and lymphoma cells. By inhibiting the BTK enzyme, ibrutinib can interfere with the signaling pathways of cancer cells, inhibit cell growth and spread, and thus slow the progression of the disease.

Ibrutinib is usually taken by mouth once daily and can be taken with or without food. Patients should always take ibrutinib as prescribed and recommended by their doctor, and receive regular medical monitoring to evaluate treatment effects and side effects.

While ibrutinib has been remarkably successful in treating certain types of leukemia and lymphoma, it can cause side effects, including bleeding tendencies, high blood pressure, abnormal liver function, fatigue, gastrointestinal discomfort, and skin reactions. Therefore, patients should pay close attention to their health status while using ibrutinib and communicate with their doctors regularly.